

# Coulter:Partners

## Top hires for VC & PE portfolio companies Q2-2020

### Search Highlights

This quarter's successful placements include:

- **CEO**, contract research organisation, Eastern Europe
- **Chief Technology Officer**, haematology products, Netherlands
- **Chief Operating Officer**, gene editing, US
- **Chief Commercial Officer**, digital health and wellbeing platform, UK
- **Chief Development Officer**, drug discovery, Belgium
- **Managing Director US**, CDMO, France
- **VP Finance**, rare diseases, Switzerland
- **VP Technical Operations**, gene therapy, US
- **Head of Discovery**, A.I. drug discovery, UK
- **VP Regulatory Affairs**, therapeutic platform, US
- **SVP Manufacturing & Supply Chain**, cell & gene therapy, Finland
- **Head of CMC**, gene editing technology, US
- **General Counsel**, immuno-oncology, UK
- **Chair**, vascular medical devices, Netherlands

Newly opened projects include:

- **CEO**, immunology platform, Germany
- **CEO**, vaccines, UK
- **CEO**, orthopaedic products, US
- **Chief Financial Officer**, life science VC, US
- **Chief Operating Officer**, healthcare services, Sweden
- **Head of DMPK**, respiratory diseases, UK
- **EVP Commercial**, laboratory services, Germany
- **Head of CMC**, cell therapy, Singapore
- **VP Client Engagement**, dental services, US
- **Director Business Operations China**, speciality pharma, Denmark
- **Chair**, oncology diagnostics, Europe
- **Associate**, life science VC, Netherlands

### Themes

Areas of focus this quarter include, but are not limited to:

- Genomics
- Women's Health
- Immuno-oncology
- A.I.
- Animal Health
- Vaccines
- Cell & Gene Therapy
- Rare Diseases
- Precision Medicine

[www.coulterpartners.com](http://www.coulterpartners.com)